Nectar Lifesciences Limited (NecLife) has sold their business of manufacturing, distribution, marketing and sale of active pharmaceutical ingredients and formulations to Ceph Lifesciences Private Limited, as a slump sale on a going concern basis; as well as their menthol business assets.
Khaitan & Co advised NecLife on sale of the API business as well as the sale, transfer and delivery of the menthol business to Ceph. The firm advised NecLife on all legal aspects of the transaction including the structuring and documentation for the transaction.
The core deal team consisted of Bhavik Narsana (Partner), Rutvik Shukla (Senior Associate), Associates Pragya Mishra and Kamayani Mittal.
Arindam Ghosh (Partner), Anvita Mishra (Counsel), Gaurang Mansinghka (Senior Associate) and Krithika Kataria (Associate) advised on Securities Laws.
Deepak Kumar (Partner) advised on Employment laws.
Incorporated in 1995, NecLife is a leading global manufacturer of cephalosporin antibiotics medicines. The Company currently has a strong hold of API & Formulation business in almost 45 countries of the world with 13 State of Art manufacturing facilities